Global Carcinoid Syndrome Pipeline Insights 2021 –

Global Carcinoid Syndrome Pipeline Insights 2021 –

Global Carcinoid Syndrome Pipeline Insights 2021 –

DUBLIN–(BUSINESS WIRE)–The “Carcinoid Syndrome – Pipeline Insight, 2021” drug pipelines has been added to’s offering.

This “Carcinoid Syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Carcinoid Syndrome pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Carcinoid Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Carcinoid Syndrome.

Carcinoid Syndrome Emerging Drugs Chapters

This segment of the Carcinoid Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Carcinoid Syndrome Emerging Drugs

Paltusotine: Crinetics Pharmaceuticals

Paltusotine, is a novel, oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonists designed for the treatment of Carcinoid Syndrome, Neuroendocrine Tumors and Acromegaly. Somatostatin is a neuropeptide hormone that broadly inhibits the secretion of other hormones, including growth hormone, or GH, from the pituitary gland.

It is designed as a once daily option for patients with acromegaly and neuroendocrine tumors that are currently treated by injected therapies. Crinetics plans to advance paltusotine into a Phase II trial for the treatment of carcinoid syndrome associated with NETs in 2021.

Carcinoid Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Carcinoid Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Carcinoid Syndrome

There are approx. 10+ key companies which are developing the therapies for Carcinoid Syndrome. The companies which have their Carcinoid Syndrome drug candidates in the most advanced stage, i.e. Phase I include, Crinetics Pharmaceuticals.


This report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Carcinoid Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Carcinoid Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Carcinoid Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Carcinoid Syndrome drugs.

Carcinoid Syndrome Report Insights

  • Carcinoid Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Carcinoid Syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Carcinoid Syndrome drugs?
  • How many Carcinoid Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Carcinoid Syndrome?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Carcinoid Syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Carcinoid Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • Aquestive Therapeutics
  • Crinetics Pharmaceuticals

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900